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Oxidative stressAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative diseasewith an adult onset characterized by loss
of both upper and lowermotor neurons. In ~10% of cases, patients developed ALSwith an apparent genetic link-
age (familial ALS or fALS). Approximately 20% of fALS displays mutations in the SOD1 gene encoding superoxide
dismutase 1. There are many proposed cellular and molecular mechanisms among which, mitochondrial
dysfunctions occur early, prior to symptoms occurrence. In this review, we modeled the effect of mutant SOD1
protein via the formation of a toxic complex with Bcl2 on mitochondrial bioenergetics. Furthermore, we discuss
that the shutdown of ATP permeation through mitochondrial outer membrane could lead to both respiration
inhibition and temporary mitochondrial hyperpolarization. Moreover, we reviewed mitochondrial calcium
signaling, oxidative stress, ﬁssion and fusion, autophagy and apoptosis in mutant SOD1-linked ALS. Functional
defects inmitochondria appear early before symptoms are manifested in ALS. Therefore, mitochondrial dysfunc-
tion is a promising therapeutic target in ALS. This article is part of a Special Issue entitled: Misfolded Proteins,
Mitochondrial Dysfunction, and Neurodegenerative Diseases.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Amyotrophic lateral sclerosis (ALS) is themost common adult-onset
motor neuron disease [1,2], with an incidence of about 2 cases per
100,000 and a prevalence of 5 per 100,000 people per year worldwide
[2]. ALS causes degeneration of upper motor neurons in the cerebral
cortex and lowermotor neurons in the brain stem and spinal cord, lead-
ing tomuscle weakness, eventually progressing to muscle paralysis and
atrophy. The most common reason of death for ALS patients is respira-
tory failure, usually within three to ﬁve years after the diagnosis [3,4].
In approximately 90% of cases, patients developed ALS without
apparent genetic linkage (sporadic ALS or sALS), while the remaining
10% of cases are familial (fALS). The ﬁrst gene discovered with ALS-
causative mutations was superoxide dismutase 1 (SOD1). More than
150 ALS-linked mutations have been reported in SOD1 over the course
of 20 years, which are cumulatively responsible for approximately 20%
of all fALS cases [5,6]. In 2011, a genetic anomaly linked to a form of
ALS associated with frontotemporal dementia (FTD) was identiﬁed as
an aberrant number of expansions of a hexanucleotide repeat sequence
(GGGGCC) in thenon-coding regionof theC9ORF72 geneon chromosomeolded Proteins, Mitochondrial
ch, Department of Neuroscience,
iversity, 900Walnut Street, JHN
.9 [7,8]. In addition to being involved in ~40% of fALS cases, these intronic
repeat expansions have been linked to ~10% of cases previously classi-
ﬁed as sporadic [9], making this the most abundant ALS-causative
gene so far. Several other mutated genes have been identiﬁed, mainly
involved in non-traditional forms of fALS or have been found in just a
few families; including VAPB (Vesicle-associated membrane protein-
associated protein B) [10], ALS2 (alsin) [11], VCP (valosin-containing
protein) [12], OPTN (optineurin) [13], UBQLN2 (ubiquilin 2) [14], DAO
(D-amino acid oxidase) [15], SPG11 [16], and hnRNPA2B1 and hnRNPA1
[17]. Cell and animal models incorporating different mutated genes
have been developed, aiming at identifying molecular mechanisms of
the disease. Among them, mice harboring mutations in the human
SOD1 transgene are still the most common genetic animal models for
this disease. In fact, most of our current understanding of themolecular
mechanisms of ALS comes from studies done on the mutant SOD1
mouse models and will be the focus of the present review.
There is currently no cure for ALS. The only FDA approved drug,
Riluzole, increases the survival in patients by a few months [18,19].
Preclinical ALS research is currently focused on the human mutant
SOD1 transgenic mouse lines, which recapitulate many aspects of
human ALS pathology and for which extended survival is one of the
main predictors of preclinical success. Several compounds have been
identiﬁed that provide some degree of improvement in survival, but
none thus far has proved to be a substantial treatment option when
translated in patients. There are multiple issues that could account for
this discrepancy, including the study design of preclinical trials, the
lack of additional animal models available for research, and insufﬁcient
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SOD1 transgenic mouse model has identiﬁed multiple cell types and
molecular mechanisms that are affected, hence single treatments that
target one pathway at a time may not be enough. Recently, a number
of investigators have begun to test combination therapies, which can
potentially enhance the effect of single pharmacological agents [20].
Many cellular and molecular mechanisms have been proposed to
explain the loss of motor neurons seen in ALS, including glutamate-
induced excitotoxicity, endoplasmic reticulum stress, proteasome inhibi-
tion, mitochondria-mediated damage, secretion of toxic factors by non-
neuronal cells, oxidative stress, axonal disorganization, neuromuscular
junction abnormalities, aberrant RNA processing [21]. In this article, we
will review the role ofmitochondria andmitochondria-mediatedmecha-
nisms of cell damage in ALS, focusing primarily on the function played by
mitochondria in the pathogenesis of mutant SOD1-ALS, sincemost of the
mechanistic studies on mitochondrial dysfunction have been done using
models of mutant SOD1-mediated ALS.
2. Mitochondria and ALS pathogenesis
That mitochondria are compromised in ALS is apparent from multi-
ple studies performed using cellular or animal models of disease and in
patients. Early studies on post-mortem tissues of ALS patients identiﬁed
at the electron microscopic level structural and morphological abnor-
malities in mitochondria of skeletal muscle, liver, spinal cord neurons
and motor cortex [22–24]. Defects in mitochondria Ca2+ buffering
capacity [25–30] and in the activity of the electron transport protein
complex occurring during the pre-symptomatic phase of disease were
also reported in the spinal cord of mutant SOD1mice [25–30]. Aberrant
mitochondria have also been identiﬁed in more recent models of
disease, as mutant FUS and TDP-43 expressing cells as well as ﬂies,
which exhibit aberrant, and perhaps, non-functional mitochondria
[31]. In the SOD1-G93A mouse model the appearance of mitochondria
with dilated and disorganized cristae has been reported, both in the
axons and dendrites of motor neurons at onset of disease [28]. In
these mice, the onset of the disease is immediately preceded by a
rapid increase in degenerating mitochondria with almost absent
motor neuron death, which progressed during the symptomatic stage
to a vacuolar pattern likely originating from expansion of themitochon-
drial intermembrane space and extension of the outer mitochondrial
membrane [32]. Mitochondria displaying swollen morphology and
increased cristae were reported in the soma and proximal axons of
motor neurons in the anterior horns of patients with sporadic ALS
(sALS) [33]. Since these morphological abnormalities appeared in mice
before the onset of symptoms and motor neuron degeneration, it has
been concluded that mitochondrial impairment plays a key role in initi-
ating motor neuron degeneration in ALS.
2.1. Mitochondria and protein misfolding in ALS
One of the pathological hallmarks of ALS is aggregation of
ubiquitinated proteins in motor neurons [34]. Most of the proteins
encoded by the known ALS causative genemutations have been identi-
ﬁed as part of these ALS-linked cellular aggregates, which include SOD1,
FUS, TDP-43, OPTN, and UBQLN2. Mutations in proteins alter their nor-
mal conformation making them unstable [35]; segregation of this phe-
nomenon with disease in familial and even sporadic cases (i.e. TDP43)
[36] suggests a causal relationship between protein instability, aggre-
gates and disease. However, whether aggregates represent a pathogenic
or simply a pathological feature of the mutated protein is still debated.
Whether there is a causal relationship between misfolded proteins
and mitochondrial dysfunction is still largely unknown for the newly
discovered ALS-linked mutations such as FUS, TDP43 and C9ORF72,
but it has been quite extensively studied in the case of mutant SOD1.
Mutant SOD1 forms insoluble aggregates inmitochondria at the surface
of outermembrane [37–39], raising the prospect of a direct cause–effectmechanism by which mutated SOD1 directly impact mitochondrial
function, ultimately leading to cell death. Indeed, isolated mitochondria
exposed in vitro to puriﬁedmutant SOD1 showed increased susceptibil-
ity to oxidative stress and structural damage, which ultimately caused
cytochrome c release [39,40].
While misfolding and oligomerization is pronounced in the
perturbed mutant SOD1 protein, it was reported that also wild type
SOD1 has the tendency to self-oligomerize, particularly in its apo state
[41,42]. Interestingly, the aggregation propensity of wild type SOD1
seemed to be balanced by the rate of self-dissociation [43]. This equilib-
riummay bedisturbed by structural alterations introduced, for instance,
by disease-causative mutations, or by age- and/or stress-induced post-
translational modiﬁcations, such as oxidation. Intriguingly, it has been
reported that posttranslationally modiﬁedwild type SOD1 is a potential
risk factor in ALS [44,45]. Oxidized SOD1 (OxSOD1) is conformationally
altered and is more prone to aggregation than its wild type counterpart
[46], similarly to what has been described for mutant SOD1-G93A [47].
Oxidized forms of wild type SOD1 have also been identiﬁed in sALS and
conformational alterations in wild type SOD1 have been proposed as a
possible pathogenic link between sALS, or at least a subset of sALS
cases, and mutant SOD1-linked fALS [47,48]. OxSOD1 and mutant
SOD1 may also hetero-oligomerize with wild type SOD1 to form aggre-
gates that could potentially be harmful to cells, similarly to what has
been reported in prion disease [49]. We previously reported that
mutant SOD1 aberrantly binds to Bcl-2 in themitochondrial outermem-
branewhere it can trigger Bcl-2mediated toxicity [40,50]. Perturbations
from thewild type state unrelated to the presence ofmutations, can also
increase SOD1 afﬁnity for Bcl-2. For instance, an iperoxidized form of
SOD1 found in a cohort of sporadic patients with bulbar ALS onset
shares toxic features with mutant SOD1-G93A as it leads to an aberrant
interaction with Bcl-2 in mitochondria and a conformational change in
Bcl-2 similar to the one induced by mutant SOD1 [48].
2.2. Possible mechanisms of mitochondrial damage induced by
mutant SOD1
One of the interacting proteins ofmutant SOD1 is Bcl-2, whichmedi-
ates, to some extent, the mutant SOD1 toxicity to mitochondria
[37,40,50]. Upon docking to mitochondria, mutant SOD1 aberrantly in-
teracts with Bcl-2 [37], which is converted into a toxic protein featuring
exposure of the BH3 death domain [40]. Bcl-2 family proteins have been
extensively characterized for their regulatory mechanisms on pro-
grammed cell death through the conformational reorganization of
their respective BH domains [51]. They also have a dual role in regu-
lating mitochondrial bioenergetics. For example, anti-apoptotic Bcl-2
family proteins, such as Bcl-xL and N-terminal truncated Mcl-1,
promote mitochondrial respiration and oxidative metabolism; while
pro-apoptotic Bcl-2 family proteins such as Bad and Noxa, when phos-
phorylated, enhance glycolysis (non-oxidative metabolism) and pen-
tose phosphate pathway [52]. By mediating BH3 domain exposure in
Bcl-2, mutant SOD1 could initially switch the bioenergetics states in
affected motor neurons by favoring glycolysis and limiting mitochon-
drial respiration. In the short term, this change in metabolism may not
necessarily have negative consequences. However, on a more extended
time scale, neurons have been shown to be particularly sensitive to dys-
regulated energy metabolism because oxidative metabolism supplies
the additional ATP necessary to sustain neuronal activity [53].
Systematic analysis of mitochondrial respiration kinetics revealed a
drop of outer membrane permeability in spinal cord mitochondria of
mutant SOD1 mice starting at pre-symptomatic stage [50], suggesting
a direct inhibition by the mutant SOD1/Bcl2 complex on VDAC1 chan-
nel, a mitochondrial porin located on the mitochondrial outer mem-
brane (MOM), which regulates mitochondrial respiration and ﬂow of
ATP through the mitochondrial outer membrane (MOM) out into the
cytosol and ADP into mitochondria for oxidative phosphorylation.
VDAC1, a key player in mitochondria-mediated apoptosis and cell
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cation selective when closed to sub-conducting states, with the pore
diameter narrowing from 3 to 1.8 nm [54]. These changes of both size
and selectivity of the channel have profound functional implications
for the permeability to ions. For small and mono-valent ions such as
K+, Cl−, H2PO4−, VDAC1 is a weak selective channel. In the closed (or
sub-conducting) states, VDAC1 becomes a cation-selective channel
with increased ion selectivity. For example, the permeability to
Ca2+ ions increases dramatically at closed states [55]. In addition,
the size change of the pore of the channel could introduce a physical
barrier to large metabolites. As a result, the closed channel becomes
virtually impermeable to large multi-valent anions such as ATP due
to the electric barrier [56]. Thus, the change in gating of VDAC1
results in a mild reduction of conductance and a rather dramatic
change in its selectivity [57] for multi-valent metabolites. Interest-
ingly, reduced ATP production has been observed in motor neurons
of mutant SOD1-G93A mice [25,58], as well as in neuroblastoma
cells expressing mutant SOD1-G37R [59].
Additional disturbances in VDAC gating mediated by the toxic mu-
tant SOD1/Bcl-2 can be predicted according to the known parameters
of mitochondrial respiration. The single channel permeability to ATP
drops from 0.7 × 105 ions/s to essentially zero at closure of VDAC,
while the permeability to creatine3−, HPO42−, succinate2− drops from
4–8 × 106 ions/s to 3 × 105 ions/s [57]. Instead, for monovalent ions
such as pyruvate and H2PO4−, there is less permeability drop in the
close states of VDAC [57]. Thus, in both open and closed states, ATP
permeability is a limiting step for a functionalmitochondrial respiration.
As VDAC closes, perhaps through the toxic function of the mutant
SOD1/Bcl-2 complex, ATP accumulates in the mitochondrial intermem-
brane space where it slows down ADP/ATP translocation through the
adenine nucleotide translocator complex (ANT). However, since metab-
olites such as pyruvate can still permeate the MOM and proceed to the
Kreb's cycle, the proton gradient through the inner membrane cannot
be dissipated. We can summarize these events in the following simpli-
ﬁed biophysical model for proton motive force (illustrated in Fig. 1).
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where [H+]o and [H+]i are the proton concentration respectively
outside and inside the matrix, k1 is the apparent kinetic constant of re-
spiratory chain complex (assuming constant substrates and enzymesFig. 1. Summarized impact of mutant SOD1/Bcl2 on mitochondria. Mutant SOD1 binds to
Bcl2, exposes its BH3 domain, and alters VDAC conducting states, resulting in reduced ATP
production, enhanced calcium signaling, increased mitochondrial potential and ROS pro-
duction. We also propose that quinone from complex I is trapped in the oxidized form.levels), k2 is the kinetic constant for ATP synthase, P is the permeability
of the inner membrane to proton.
At steady state, k1[H+]i− k2[ADP][H+]o− P([H+]o− [H+]i) = 0.
Therefore,
Hþ
 
o
Hþ½ i
¼ k1 þ P
k2 ADP½ −P
Δm ¼ Δpþ 59 log
k1 þ P
k2 ADP½ −P
where Δm is the mitochondrial membrane potential, Δp is the proton
motive force. Closure of VDAC mediated by the mutant SOD1/Bcl-2
complex can, therefore, slow down the ADP/ATP permeation through
the MOM, decreasing ADP levels available in the intermembrane space
and matrix for ATP synthase to produce ATP and therefore dissipate
the proton gradient, ultimately inducing mitochondrial hyperpolari-
zation. In reality, mitochondrial substrate concentrations such as
NAD/NADH ratio could affect the parameters above. This simpliﬁed
model provides a quantitative approach to understand the effects of
intermembrane space ADP concentration on the mitochondrial mem-
brane potential and thus it is more related to the transient effects of
VDAC closure on mitochondria.
We found that a speciﬁc SOD1-mimetic peptide can restore normal
mitochondrial membrane potential and VDAC1 permeability by lessen-
ing the interaction between mutant SOD1 and Bcl-2. Studies in other
pathological conditions would also seem consistent and supportive of
this model. For example, the anti-cancer drug G3139, which closes
VDAC channel and causes apoptosis in cancer cells, also induces mito-
chondrial hyperpolarization (Colombini M., personal communication).
Hyperpolarization state can lead to reactive oxygen species (ROS) gen-
eration by Complex I [60]. These two important aspects ofmitochondri-
al dysfunction have also been reported in ALS [50] andwill be discussed
in the next section.
Other lines of evidence pointing at defective mitochondrial bioener-
getics as the leadingmechanism inmitochondria-mediated cell damage
have also been identiﬁed in ALS, including mutation in cytochrome c
oxidase subunit I [61], mutations in mitochondrial tRNA gene [62],
complex I deﬁciency and decreased ATP/ADP ratio [63].
2.3. Calcium signaling and mitochondria in ALS
Increased oxidative phosphorylation and ATP production is required
during action potential ﬁring in neurons. During each cycle, Ca2+ is
released from the endoplasmic reticulum (ER) stores, enters mitochon-
dria, buffers in thematrix, andﬁnally is extruded from themitochondria
and taken up by the ER. Therefore, there is a resilient; tightly regulated
ER-mitochondrial coupled Ca2+ signaling in neurons. Because neurons
ﬁre action potentials repeatedly in a millisecond time scale, they are
also particularly susceptible to mitochondria and ER stress or impair-
ment leading to calcium dysregulation.
VDAC actively participates in the mitochondrial-ER Ca2+ coupling.
VDAC channels (mainly VDAC1) are expressed close to the mitochon-
drial-ER tether sites, where Ca2+ permeable channels such as inositol
triphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) are
expressed at the ER side [64,65]. There are direct local Ca2+ ﬂuxes
from ER to mitochondria, to expedite the whole process [64,65]. Calci-
um ions enter mitochondrial matrix via the mitochondrial calcium
uniporter (MCU) with the support of mitochondrial calcium uptake 1
(MICU1) by following the electrochemical gradient [66,67]. Several
lines of evidence showed that calcium uptake activity is impaired in
ALS. For example, mutant SOD1 affects Ca2+ uptake in ALS-affected tis-
sues such as spinal cord but not in ALS-spared tissues such as liver [27].
It has recently been shown that the activity of MCU and MICU1 is de-
pressed in the SOD1-G93A mouse model, even though the expression
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[68]. This may lead to a decreased Ca2+ buffering capacity inmitochon-
dria of thesemice. Indeed, evidence of defective Ca2+ buffering capacity
has been reported prior to onset in neuronal mitochondria of SOD1-
G93Amice [27]. In addition, SOD1-G93Amotor neurons have higher in-
tracellular calcium levels [69], leading to possible Ca2+ overload to mi-
tochondria. It is well-established that Ca2+ overload results in
mitochondrial permeability transition [70]. In line with this, multiple
groups have examined how knockdown of CyPD, the only conﬁrmed
component of mitochondrial permeability transition pore, affects the
survival of mutant SOD1 mice. Although the results are conﬂicting, it
is the general consensus that Ca2+ overloads affect motor neuron sur-
vival [71–74].
2.4. Oxidative stress and mitochondria in ALS
Unrestrained production of ROS by mitochondria has been consid-
ered as one possible cause of neurodegeneration in ALS [75]. This belief
is based on a number of circumstantial evidence: 1) Increased oxidative
stress and ROS damage characterized by elevated protein carbonylation
and tyrosine nitration have been observed in CNS tissues from ALS pa-
tients [76–80]; 2) A conformation speciﬁc antibody (B8H10) recognizes
misfolded mutant SOD1 proteins in ALS spinal cord mitochondria,
which displayed ROS accumulation [39], conﬁrming a role formisfolded
mutant SOD1 in mitochondrial dysfunction and elevated ROS produc-
tion; 3) ROS actively participates in the disease progression in mutant
SOD1 ALS mouse models. SOD1-G93A transgenic mice crossed with
mice deﬁcient in the mitochondrial matrix antioxidant enzyme
MnSOD (Sod2+/−mice) caused a decrease in lifespan thatwas associat-
ed with a reduced disease duration [81]. However, in the same report,
MnSOD1 deﬁciency does not affect the disease states of metal deﬁcient
H46R/H48Qmutant SOD1 ALSmice [97]. Therefore, different ALSmuta-
tions may affect mitochondria through different mechanisms. ROS
production appeared to participate in motor neuron death pathways
in some ALS models, although perhaps not a determining factor.
There are several types of ROS and reactive nitrogen species (RNS)
that are formed in cells including superoxide anions, hydrogen perox-
ide, hydroxyl radicals, organic hydroperoxides, hypochlorous acid,
peroxynitrite [82]. Endogenously, these compounds modulate different
signaling pathways and their formation is tightly regulated [83,84].
However, when produced at higher levels, they can target and react
with lipid membranes, proteins and nucleotides, thus accelerating cell
senescence and eventually cause cell death. Most of the oxidative spe-
cies are formed from superoxide anions generated by mitochondrial
respiration. Therefore, superoxide anion generation in mitochondria is
the most critical point that directly initiates all the oxidative stress
signals. Superoxide anions can be generated from both complex I and
complex III, depending on the organs [85]. In the CNS, most superoxide
is generated by complex I [85], whose activity is decreased in lympho-
cytes of ALS patients [63,86–88]. The deﬁciency in complex I is associated
with ROS production in the mitochondria [89–91]. Therefore, this defect
may be the source of oxidative stress in ALS.
2.5. Fission and fusion of mitochondria in ALS
Mitochondria are very dynamic and intensively interconnected or-
ganelles that form tubular networks across the whole cell [92]. They
constantly undergo ﬁssion and fusion in order to meet different
cellular demands. This mitochondrial network remodels under stress
conditions [93], changing in energy demand and Ca2+ levels [94].
Remodeling the mitochondrial network also serves the purpose of
repairing damaged mitochondria and coping with increases in Ca2+
waves [95]. Any alteration in this process of ﬁssion and fusion in the
nervous system can cause cell damage and eventually lead to
neurodegeneration [96]. For example, mutations in PINK1 and Parkin,
two important proteins that promote mitochondrial ﬁssion and inhibitfusion [97], cause alterations in mitochondrial dynamics and cause
Parkinson's disease (PD), thus suggesting an active role for
dysfunctional mitochondrial ﬁssion and fusion dynamics in PD patho-
genesis. Similar alterations have been reported in ALS, Pro-fusion
OPA1 protein levels are decreased, while pro-ﬁssion phosphor-DRP1
protein levels are increased in mutant SOD1 mice [98]. Overexpression
of Glutaredoxin 2, which regulates mitochondrial fragmentation, pre-
serves mitochondrial function and dynamics by restoring DRP1 and
OPA1 levels and strongly protects neuronal cells from apoptosis [98]. In-
creased mitochondrial fragmentation (ﬁssion) was recently reported in
differentiated NSC34 cells transfected with different mutant SOD1 pro-
teins [24,99]. It is worth noting that the processes of mitochondrial ﬁs-
sion/fusion and apoptosis/mitophagy share common mechanisms. For
example, Bcl-xL increases both ﬁssion and fusion of mitochondria,
which ultimately lead to a rise in mitochondrial biomass as net out-
come [100]. Exposure of the BH3 domain in Bcl-2 by mutant SOD1
[40] could potentially affect the ﬁssion and fusion machinery in mito-
chondria as BH3 domain only proteins like Bax and Bak also increase
mitochondrial ﬁssion. Changes in mitochondrial dynamics also involve
both anterograde and retrograde transport of mitochondria in neurons
that ultimately die in ALS [101] and are speciﬁc to mutant SOD1 motor
neuron mitochondria, since they are absent in wild-type SOD1 motor
neurons, they do not involve other organelles, and they are not found
in neurons not affected by ALS, like cortical neurons [102].
2.6. Consequences of mitochondrial damage
ALS-altered mitochondria may trigger apoptosis and ultimately cell
death by inducingmitochondrial release of cytochrome c [103]. Howev-
er, whether mitochondrial initiated apoptosis plays an essential role in
neurodegeration is still a matter of dispute. Knocking out the pro-
apoptotic protein Bax in mutant SOD1-G93A mice prevents death of
motor neurons and delays disease onset and progression, but
mitochondrial degeneration still occurs [104], suggesting that
mitochondria-initiated apoptosis in motor neurons could only be a
secondary effect [105,106]. Interestingly, knockout of both Bax and
Bak (two pro-apoptotic Bcl-2 family proteins) signiﬁcantly extends sur-
vival of SOD1-G93Amice [107]. As Bax and Bak have similar function in
forming pores in the mitochondrial outer membrane through which
cytochrome c can be released [108], these results suggest a redundant
mechanism of mitochondria-initiated toxicity between these two pro-
teins, and point at the importance of mitochondria altered perme-
abilization in the pathogenesis of ALS.
Mitochondria are very abundant in nerve terminals where they
serve the purpose of providing energy and regulate Ca2+ waves. There-
fore, theremust be robust coordination between synaptic activity, mito-
chondrial transport/distribution, and ATP generation. However, in
mutant SOD1 mice, both anterograde and retrograde axonal transport
are slowed down due to disruption of the neuroﬁlament network
[109,110] and accumulation of insoluble proteins [111]. Therefore, deﬁ-
ciency in mitochondrial transport [112], hence inability to replace
uncoupled mitochondria at the neuromuscular terminals, can trigger
the disease through a “dying back”mechanism. For example, evidence
of motor axon degeneration occurring prior to motor neuron death
has been reported in mutant SOD1-linked ALS [111]. In the mutant
SOD1 mice, quantitative analysis reveals the weakening of NMJ early
during the presymptomatic stage of disease, followed by loss of motor
axons at symptomatic stage [106]. This “dying back” mechanism has
been observed in other neurodegenerative diseases as well [113] and
is compatible with “mitochondrial-mediated”mechanism of neurode-
generation as enlarged mitochondria were ﬁrst observed in the distal
part of the nerve terminal at the pre-symptomatic stage [114]. These
mitochondrial damages are also not limited to motor neurons, e.g., NMJ
deterioration and axonal degeneration occurs when the efﬁciency of
mitochondria dependent oxidative phosphorylation is inhibited by over-
expression of uncoupling protein 1 (UCP1) in themuscle cells [115]. Also,
Fig. 2.Kineticmodel of generation of proton gradient (not drawn to scale). ADP permeates
through VDAC channels in the outer membrane, translocates through ANT in the inner
membrane, where it is phosphorylated into ATP inside the matrix by ATP synthase
through dissipation of proton gradient, with apparent kinetic constant of k2. The proton
gradient is generated through respiratory complexes with apparent kinetic constant of
k1 and subjected to leakage through the inner membrane.
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was observed inmuscle cells prior toNMJ destruction [116], further prov-
ing evidence for mitochondrial dysfunction as one of the early mecha-
nism of the disease.
2.7. Perspectives and conclusions
Since the ﬁrst reports on mitochondrial abnormalities in tissues
from ALS patients, several lines of evidence gathered from studies sub-
sequently done on the mutant SOD1mouse and cell models expressing
mutant SOD1 proteins have pointed at mitochondrial dysfunction as
cause of motor neuron death in ALS. One example is the recent observa-
tion that VDAC1 channel can enter less conductive (closed) states by
directly interacting with mutant SOD1 [117]. Bcl-2 is a mitochondrial
outer membrane protein that directly regulates VDAC activity and
these two proteins are very tightly associated. In this respect, we
showed that at the mitochondria, mutSOD1 forms a toxic complex
with Bcl-2, which is then converted into a toxic protein via a structural
rearrangement that exposes its toxic BH3 domain (Pedrini et al., 2010).
The formation of this toxic complex with Bcl-2 is the primary event in
mutSOD1-inducedmitochondrial dysfunction, inhibitingmitochondrial
permeability to ADP and inducingmitochondrial hyperpolarization, cal-
cium stress and ROS production (Fig. 2). In mutSOD1-G93A cells and
mice, the newly exposed BH3 domain in Bcl-2 alters the normal interac-
tion between Bcl-2 and VDAC1 thus reducing permeability of the outer
mitochondrial membrane. In motor neuronal cells, the mutSOD1/Bcl-2
complex causes mitochondrial hyperpolarization leading to cell loss
[50]. In addition, alterations in mitochondrial metabolism could be
one of the disease mechanisms, as knocking down VDAC1 in mutant
SOD1 ALS mice, accelerates the onset of the disease [117], suggesting
that mitochondrial bioenergetics is critical for the good health of
motor neurons. Increased mitochondrial Ca2+ storage capacity reduces
aggregation ofmisfolded SOD1 andmotor neuron cell death. Surprising-
ly, this does not seem to extend survival in mouse models of inherited
ALS [72]. At minimum, motor neuron death is, however, an essential
measurement of disease progression, but it is possible that the ﬁnal
muscle paralysis event is independent from motor neuron loss. Never-
theless, this result is puzzling and needs further cross-examination,
since at least in multiple sclerosis, a similar approach does protect
motor axons and enhances recovery [118].Mitochondrial dysfunction is not only observed in SOD1 ALS but has
also been seen in familial cases involved with FUS, TDP43 and sporadic
cases [119]. In summary, thewealth of evidence published thus far leads
to the conclusion thatmitochondrial dysfunction occurs early in disease
and it is one key mechanism responsible for the degeneration of motor
neurons in ALS.
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